Velázquez-Acosta C, Cornejo-Juárez P, Volkow-Fernández P

Language: Spanish
References: 19
Page: 151-157
PDF size: 587.83 Kb.

ABSTRACT

Objective. To describe the trend of multidrug resistant (MDR) strains isolated from blood in patients with cancer from 2005 to 2015. Materials and methods. 33 127 blood cultures were processed by retrospective analysis. Identification and antimicrobial sensitivity were performed through automated methods: WaLK away (Siemens Laboratory Diagnostics) and BD Phoenix (Becton, Dickinson and Company). Resistant strains were determined according to the minimum inhibitory concentration, following the parameters of the Clinical and Laboratory Standards Institute (CLSI). Results. Of 6 397 isolates, 5 604 (16.9%) were positive; 3 732 (58.4%) Gram- bacilli; 2 355 (36.9%) Gram+ cocci; 179 (2.7%) yeasts, and 126 (1.9%) Gram+ bacilli. Escherichia coli (n=1 591, 24.5%) was the most frequent bacteria, with 652 (41%) strains being extended-spectrum beta-lactamases producers (ESBL); of Enterococcus faecium (n=143, 2.1%), 45 (31.5%) were vancomycin resistant; of Staphylococcus aureus (n=571, 8.7%), 121 (21.2%) methicillin resistant (MRSA); of Klebsiella pneumoniae (n=367, 5.6%), 41 (11.2%) ESBL; of Acinetobacter baumanii (n=96, 1.4%), 23 (24%) MDR, and of Pseudomonas aeruginosa (n=384, 5.6%), 43 (11.2%) MDR. MDR strains were significantly more frequent in patients with hematological malignancies, compared to those with solid tumors: MRSA (OR=4.48, 95%CI 2.9-6.8), ESBL E. coli (OR=1.3, 95%CI 1.10-1.65) and MDR Acinetobacter baumanii (OR=3.2, 95%CI 1.2-8.3).Conclusions. We observed significantly higher isolations of E-ESPAKE MDR strains in patients with hematological malignancies.

REFERENCES

1. Espinosa-Rivera F, Hart-Casares M, Halley-Posada MC, Martínez- Batista ML, Pardo-Núñez A. Resistencia bacteriana de cepas aisladas en el Hospital “Hermanos Ameijeiras”. Rev Cubana Med. 2008;47(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75232008000400002&lng=es

2. Cornejo-Juárez P, Pérez-Jiménez C, Silva-Sánchez J, Velázquez-Acosta C, González-Lara F, Reyna-Flores F, et al. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies. PLoS One. 2012;7(4):e35780. https://doi.org/10.1371/journal.pone.0035780

3. Deneve C, Janoir C, Poilane I, Fantinato C, Collignon A. New trends in Clostridium difficcile virulence and pathogenesis. Int J Antimicrob Agents. 2009;33(suppl 1):S24-8. https://doi.org/10.1016/S0924-8579(09)70012-3

4. Martínez-Martínez L, Clavo J. The growing problem of antibiotic resistance in clinically relevant Gram-negative bacteria current situation. Enf Infecc Microbiol Clin. 2010:28(suppl 2):25-31.

5. Fariñas MC, Martínez-Martínez L.Infecciones causadas por bacterias gramnegativas multirresistentes. Enf Infecc Microbiol Clin. 2013:31(6):402-9. https://doi.org/10.1016/j.eimc.2013.03.016

6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 33th Informational supplement, vol. 32, núm. 3. Approved Standard M100-S22. Wayne, PA: CLSI, 2012.

7. Shallcross LJ, Davies SC. The World Health Assembly resolution on antimicrobial resistance. J Antimicrob Chemother. 2014;69(11):2883-5. https://doi.org/10.1093/jac/dku346

8. Chioro A, Coll-Seck AM, Høie B, Moeloek N, Motsoaledi A, Rajatanavin R, et al. Antimicrobial resistance: a priority for global health action. Bull World Health Organ. 2015;93(7):439. https://doi.org/10.2471/BLT.15.158998

9. Cornejo-Juárez P, Velázquez-Acosta C, Diaz-González A, Volkow-Fernández P. Trend of antimicrobial drug-susceptibility of blood isolates at an oncological center (1998-2003). Salud Publica Mex. 2005;47(4):288-93.

10. Metzger KE, Rucker Y, Callaghan M, Churchill M, Jovanovic BD, Zembower TR, et al. The burden of mucosal barrier injury laboratoryconfirmed bloodstream infection among hematology, oncology, and stem cell transplant patients. Infect Control Hosp Epidemiol. 2015;36(2):119-24. https://doi.org/10.1017/ice.2014.38

11. Cornejo-Juárez P, Vilar-Compte D, García-Horton A, López- Velázquez M, Ñamendys-Silva S, Volkow-Fernández P. Hospital-acquired infections at an oncological intensive care cancer unit: differences between solid and hematological cancer patients. BMC Infect Dis. 2016;16:274. https://doi.org/10.1186/s12879-016-1592-1

12. Mehl A, Åsvold BO, Kümmel A, Lydersen S, Paulsen J, Haugan I, et al. Trends in antimicrobial resistance and empiric antibiotic therapy of bloodstream infections at a general hospital in Mid-Norway: a prospective observational study. BMC Infect Dis. 2017;17(1):116. https://doi.org/10.1186/s12879-017-2210-6

13. Son JS, Song JH, Ko KS, Yeom JS, Ki HK, Kim SW, et al. Bloodstream infections and clinical significance of healthcare-associated bacteremia: a multicenter surveillance study in Korean hospitals. J Korean Med Sci. 2010;25(7):992-8. https://doi.org/10.3346/jkms.2010.25.7.992

14. Singhal T, Shah S, Naik R. The microbial etiology and antimicrobial susceptibility of bloodstream infections in patients with cancer at a private tertiary care hospital in Mumbai, India. Indian J Cancer. 2016;53(3):452-3.

15. Sengar M, Kelkar R, Jain H, Biswas S, Pawaskar P, Karpe A. Frequency of bacterial isolates and pattern of antimicrobial resistance in patients with hematological malignancies: A snapshot from tertiary cancer center. Indian J Cancer. 2014;51(4):456-8. https://doi.org/10.4103/0019-509X.175387

16. Alatorre-Fernández P, Mayoral-Terán C, Velázquez-Acosta C, Franco- Rodríguez C, Flores-Moreno K, Cevallos MA, et al. A polyclonal outbreak of bloodstream infections by Enterococcus faecium in patients with hematologic malignancies. Am J Infect Control. 2017;45(3):260-6. https:// doi.org/10.1016/j.ajic.2016.10.002

17. Ñamendys-Silva SA, Correa-García P, García-Guillén FJ, González- Herrera MO, Pérez-Alonso A, Texcocano-Becerra J, et al. Outcomes of critically ill cancer patients with Acinetobacter baumannii infection. World J Crit Care Med. 2015;4(3):258-64. https://doi.org/10.5492/wjccm.v4.i3.258

18. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl):1995-2025. https://doi.org/10.1002/cncr.20162

19. Peralta A, Volkow P. Infecciones en pacientes con leucemia aguda en quimioterapia en el Instituto Nacional de Cancerología (INCan). Memorias XL Congreso Anual de la Asociación Mexicana de Infectología y Microbiología Clínica. Enfermedades Infecciosas y Microbiología. 2015;35(Suppl):S54.